Stimulation of an anti-tumor immune response with “chromatin-damaging” therapy-Reference-Cited by-同舟云学术

Stimulation of an anti-tumor immune response with “chromatin-damaging” therapy

Published:2021-01-13 Issue:7 Volume:70 Page:2073-2086
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Chen Minhui,Brackett Craig M.,Burdelya Lyudmila G.,Punnanitinont Achamaporn,Patnaik Santosh K.,Matsuzaki Junko,Odunsi Adekunle O.,Gudkov Andrei V.,Singh Anurag K.,Repasky Elizabeth A.^ORCID,Gurova Katerina V.^ORCID

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-020-02846-8.pdf

Reference56 articles.

1. Mouw KW, Goldberg MS, Konstantinopoulos PA, D’Andrea AD (2017) DNA damage and repair biomarkers of immunotherapy response. Cancer Discov 7(7):675–693. https://doi.org/10.1158/2159-8290.CD-17-0226

2. Klinakis A, Karagiannis D, Rampias T (2020) Targeting DNA repair in cancer: current state and novel approaches. Cell Mol Life Sci 77(4):677–703. https://doi.org/10.1007/s00018-019-03299-8

3. Souliotis VL, Vlachogiannis NI, Pappa M, Argyriou A, Ntouros PA, Sfikakis PP (2019) DNA damage response and oxidative stress in systemic autoimmunity. Int J Mol Sci. https://doi.org/10.3390/ijms21010055

4. Sun L, Wu J, Du F, Chen X, Chen ZJ (2013) Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339(6121):786–791. https://doi.org/10.1126/science.1232458

5. Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Rohl I, Hopfner KP, Ludwig J, Hornung V (2013) cGAS produces a 2’-5’-linked cyclic dinucleotide second messenger that activates STING. Nature 498(7454):380–384. https://doi.org/10.1038/nature12306

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chromatin as an old and new anticancer target;Trends in Cancer;2024-08

2. Manipulating Radiation‐Sensitive Z‐DNA Conformation for Enhanced Radiotherapy;Advanced Materials;2024-05-09

3. CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers;2024-02-20

4. The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin’s lymphoma tumor growth by promoting apoptosis and autophagy;Cell Communication and Signaling;2023-01-23

5. Carboplatin enhances lymphocyte-endothelial interactions to promote CD8+ T cell trafficking into the ovarian tumor microenvironment;Gynecologic Oncology;2023-01